John Connolly synced with the folks at the Parker Institute for Cancer Immunotherapy early on. As the science chief at Singapore-based Tessa Therapeutics, he worked on a next-gen CAR-T with an amped up package of T cells. But the same immunotherapy focus runs right through his days teaching at Baylor